Why focus on solid tumors?
Solid tumors represent 9 out of 10 human cancers
2 in 3 cancer deaths are caused by metastasizing solid tumors
Only < 1 in 5 patients
responds to available
therapy
Development timelines
Discovery
Lead Optimization
Pre-Clinical
Phase I
- Pre-Clinical
ADC
YB-811
- Lead Optimization
BiTCE
YB-820
BiTCE
YB-821
- Pre-Clinical
RPT
YB-830
RPT
YB-831
RPT
YB-832
- Discovery
CAR-T
YB-840
Development timelines
- Discovery
CAR-T
YB-840
- Lead Optimization
BiTCE
YB-820
BiTCE
YB-821
- Pre-Clinical
ADC
YB-811
RPT
YB-830
RPT
YB-831
RPT
YB-832
- Phase 1